Poxvirus Infections - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 43 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Poxvirus Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Poxvirus Infections - Pipeline Review, H2 2014', provides an overview of the Poxvirus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Poxvirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Poxvirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Poxvirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Poxvirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Poxvirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Poxvirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Poxvirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Poxvirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Poxvirus Infections Overview 6
Therapeutics Development 7
Pipeline Products for Poxvirus Infections - Overview 7
Pipeline Products for Poxvirus Infections - Comparative Analysis 8
Poxvirus Infections - Therapeutics under Development by Companies 9
Poxvirus Infections - Therapeutics under Investigation by Universities/Institutes 10
Poxvirus Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Poxvirus Infections - Products under Development by Companies 14
Poxvirus Infections - Products under Investigation by Universities/Institutes 15
Poxvirus Infections - Companies Involved in Therapeutics Development 16
BioApex, s.r.o. 16
SIGA Technologies, Inc. 17
Takeda Pharmaceutical Company Limited 18
Poxvirus Infections - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
4-ThioIDU - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Antibody for Poxvirus Infections - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BA-368 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
modified vaccinia ankara vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule to Inhibit DNA Synthesis for Viral Infections - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit Viral DNA Polymerase for Herpes and Poxvirus Infections - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
tecovirimat - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Poxvirus Infections - Recent Pipeline Updates 38
Poxvirus Infections - Dormant Projects 40
Poxvirus Infections - Product Development Milestones 41
Featured News & Press Releases 41
Mar 12, 2013: Siga Delivers First Courses Of Arestvyr To US Strategic National Stockpile Under BARDA Contract 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products under Development for Poxvirus Infections, H2 2014 7
Number of Products under Development for Poxvirus Infections - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Comparative Analysis by Unknown Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Poxvirus Infections - Pipeline by BioApex, s.r.o., H2 2014 16
Poxvirus Infections - Pipeline by SIGA Technologies, Inc., H2 2014 17
Poxvirus Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Poxvirus Infections Therapeutics - Recent Pipeline Updates, H2 2014 38
Poxvirus Infections - Dormant Projects, H2 2014 40